1542706-15-9

Upstream product

• 52488-36-5 4-bromo-1H-indole 
• 1542711-55-6 N-benzyl-2-chloro-7,8-di-hydro-5H-pyrano[4,3-d]pyrimidin-4-amine 
• 944902-88-9 2,4-dichloro-7,8-dihydro-5H-pyrano[4,3-d]pyrimidine 
• 1478126-83-8 7, 8-dihydro-5H-pyrano[4,3-d]pyrimidine-2,4-diol 
• 1542711-49-8 methyl 4-amino-5,6-dihydro-2H-pyran-3-carboxylate 
• 127956-11-0 4-oxotetrahydro-2H-pyran-3-carboxylic acid methyl ester 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 1542706-34-2 1-(4-(benzylamino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxylic acid 
• 74-89-5 methylamine 
• 34058-51-0 methyl 2-methyl-1H-indole-4-carboxylate 
• 6127-18-0 4-bromo-2-methyl-1H-indole 
• 1232861-11-8 4-bromo-2-methyl-1-(phenylsulfonyl)-1H-indole 
• 412048-77-2 1‐(benzenesulfonyl)‐4‐bromo‐1H‐indole 

Relevant academic research and scientific papers

FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX

Fused pyrimidine compounds having a saturated, unsaturated or aromatic A ring fused to a pyrimidine ring and having a complex substituents at the 2 position and a substituted amine at the 4 position of the pyrimidine ring as well as optional aliphatic, functional and/or aromatic components substituted at other positions of the pyrimidine ring and A ring are disclosed. These compounds are inhibitors of the AAA proteasome complex containing p97 and are effective medicinal agents for treatment of diseases associated with p97 bioactivity such as cancer.